The 3-week NASH mouse, a rapid preclinical model of NASH, to be presented at the Keystone on Obesity and NAFLD
Physiogenex will be presenting its innovative 3-week NASH mouse model of NASH – Fibrosis at the Keystone on Obesity and NAFLD in Banff, Alberta, Canada, February the 23th – 27th, 2020.
Liraglutide and elafibranor improve NASH in the 3-week NASH mouse model
Dr François Briand, our Director of Research and Development, will be presenting a poster (#1011) about the effects of liraglutide and elafibranor in the 3-week NASH mouse during the poster session on Monday February the 24th, 2020 from 7:30pm to 10:00pm.
Feel free to contact us if you wish to meet Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.